Accepted Manuscript

Motivating factors for dual method contraceptive use among adolescents and young women: A qualitative investigation

Julie Lemoine, Stephanie B. Teal, Marissa Peters, Maryam Guiahi

PII: S0010-7824(17)30185-3

DOI: doi: 10.1016/j.contraception.2017.06.011

Reference: CON 8928

To appear in: Contraception

Received date: 31 March 2017 Revised date: 15 June 2017 Accepted date: 21 June 2017



Please cite this article as: Lemoine Julie, Teal Stephanie B., Peters Marissa, Guiahi Maryam, Motivating factors for dual method contraceptive use among adolescents and young women: A qualitative investigation, *Contraception* (2017), doi: 10.1016/j.contraception.2017.06.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Motivating factors for dual method contraceptive use among adolescents and young women: A qualitative investigation

Julie Lemoine, MD^a, Stephanie B. Teal, MD, MPH^a, Marissa Peters, MPH^b, Maryam Guiahi, MD, MSc^a

- a. University of Colorado, Department of Obstetrics and Gynecology, Division of Family Planning; 13001 E 17th Pl, Aurora, CO 80045 USA
- University of North Carolina at Chapel Hill, Carolina Population Center 206 W. Franklin Street, Chapel Hill, NC 27516 USA

Corresponding Author:

Maryam Guiahi, MD, MSc 12631 E. 17th Avenue B198-2 Aurora, CO 80045 303-724-2038 (Work), 708-860-8929 (Cell) 303-724-2056 (Fax) maryam.guiahi@ucdenver.edu

Word Count: Abstract: 249; Manuscript: 2,438

Potential conflicts of interest: Dr. Teal served on scientific advisory boards of Actavis and Bayer Healthcare, and serves on a Data Monitoring Board for a study funded by Merck and Co. The University of Colorado Department of Obstetrics and Gynecology has received research funding from Bayer, Agile Therapeutics, Merck and Co, and Medicines 360. All other authors report no potential conflicts of interest.

This work was presented as an oral abstract at the North American Society for Pediatric and Adolescent Gynecology, Toronto, Ontario, April 7, 2016.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Download English Version:

https://daneshyari.com/en/article/5694112

Download Persian Version:

https://daneshyari.com/article/5694112

Daneshyari.com